p53<i>abn</i> high-risk endometrial cancer with <i>PPP2R1A</i> mutation might not benefit from adjuvant chemotherapy
PPP2R1A and FBXW7 status may be related to the current adjuvant chemotherapy outcome, particularly in endometrial cancer with the p53abn subtype. Thus, incorporating PPP2R1A and FBXW7 detection in the stratification and treatment decision-making process may be helpful.
Authors
- Suxia Wang (ORCID: https://orcid.org/0000-0001-7631-6464)
- Jimeng Sun (ORCID: https://orcid.org/0000-0003-1512-6426)
- Yue Wang (ORCID: https://orcid.org/0000-0001-9697-6734)
- Yan Zhang (ORCID: https://orcid.org/0000-0002-7111-7164)
- Dong Li (ORCID: https://orcid.org/0000-0003-4129-2268)
- Xin Li (ORCID: https://orcid.org/0000-0001-6432-3966)
- Qingxia Zhang (ORCID: https://orcid.org/0000-0002-9264-9039)
- Dan He
- Ying Dong (ORCID: https://orcid.org/0000-0002-7367-8862)
Institutions
- Peking University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-05-25
- DOI
- https://doi.org/10.1093/ajcp/aqaf039
- Citations
- 2
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.11